Episode Details
Back to Episodes
A New Scan May Detect Glaucoma Progression Years Before It Shows Up on a Visual Field Test
Description
This audio article is from VisualFieldTest.com.
Read the full article here: https://visualfieldtest.com/en/a-new-scan-may-detect-glaucoma-progression-years-before-it-shows-up-on-a-visual-field-test
Test your visual field online: https://visualfieldtest.com
Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support
Excerpt:
A New Scan May Detect Glaucoma Progression Years Before It Shows Up on a Visual Field Test Introduction A study published online on September 3, 2026, reported that optical coherence tomography angiography, or OCTA, detected event-based glaucoma progression an average of 2.3 years before visual-field progression. Conventional structural optical coherence tomography, or OCT, detected progression about 1.5 years before visual-field progression. JAMA Ophthalmology study () That sounds like a major breakthrough. It could imply that clinicians might identify worsening glaucoma long before patients lose measurable vision. However, the result needs careful interpretation. The study did not prove that OCTA detects the biological beginning of glaucoma damage two years earlier. It showed that an OCTA measurement crossed a predefined statistical threshold before a visual-field algorithm crossed its own threshold. Those are not necessarily the same thing. The most defensible conclusion is: > OCTA may provide an earlier vascular signal of progression in some eyes, but the evidence does not yet show that it reliably outperforms the best structural OCT strategy or that every OCTA alert represents irreversible retinal ganglion-cell loss. The New Study: What It Actually Found Study design and participants The study used patients from the Diagnostic Innovations in Glaucoma Study, a longitudinal research cohort. It included: 116 patients 180 eyes 111 eyes with perimetric glaucoma, meaning repeatable visual-field damage was already present 69 preperimetric eyes, meaning glaucomatous optic-nerve or structural damage was present without repeatable visual-field loss Mean age: 67.6 years Mean follow-up: 5.1 ± 1.4 years Minimum eligibility: at least 2 years of follow-up and at least four visits with each testing method The public abstract does not provide a detailed breakdown into mild, moderate, and advanced glaucoma. Therefore, it is not possible to know from the published abstract whether the two-year lead time was concentrated in early disease, moderate disease, advanced disease, or spread evenly across stages. JAMA Ophthalmology study () What was measured? The study compared: OCTA vessel-density change Circumpapillary retinal nerve fiber layer thickness change, measured by structural OCT Visual-field progression The abstract states that OCT and OCTA progression were defined as a change exceeding test-retest variability at two consecutive visits. Visual-field progression was assessed using the instrument’s Guided Progression Analysis. Important details are not available in the public abstract: The exact OCTA device The scan size Whether the main metric was peripapillary vessel density, optic-nerve-head vessel density, macular vessel density, or a combined measure The exact retinal slab The numerical test-retest thresholds Whether visual-field progression meant “possible” or “likely” Guided Progression Analysis progression Whether the structural OCT algorithm used only event analysis or also a slope-based trend analysis These missing details matter because OCTA vessel-density values are highly dependent on the device, scan size, software version, segmentation method, signal strength, and region measured. A related 2024 study from the same research group used an Optovue Avanti AngioVue system, wit